Further immunohistochemistry and in vitro studies investigating the activation and functional roles of Bad and Forkhead-family factors in BO and OAC are required to confirm or refute these hypotheses as well as define further downstream Akt targets but both of these would potentially provide new targets for both chemotherapeutic intervention and improved diagnosis. This evidence concerns the gene BAD and bronchiolitis obliterans syndrome.